The results are really good, normally when a drug has a successful effect phase 2 there’s still a lot of doubt about passing a phase 3, but this is where the success of trofinitide in its phase 3 trial will do away with a lot of doubt people may have of this passing phase 3 as well.
NEU will also have the benefit of reworking the trial design if desired so all secondary endpoints are met - but this may just happen anyway with an increase in patient numbers
Ann: P2 trial shows significant improvements in Phelan-McDermid, page-40
-
- There are more pages in this discussion • 171 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.21 |
Change
-0.270(1.74%) |
Mkt cap ! $1.944B | |||
| Open | High | Low | Value | Volume |
| $15.20 | $15.33 | $15.02 | $8.268M | 543.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 700 | $15.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.24 | 220 | 1 |
View Market Depth
| Last trade - 16.10pm 22/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |